BeOne Medicines (NASDAQ:ONC) SVP Sells $103,447.88 in Stock

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) SVP Chan Henry Lee sold 332 shares of the stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $311.59, for a total transaction of $103,447.88. Following the completion of the transaction, the senior vice president directly owned 318,370 shares of the company's stock, valued at approximately $99,200,908.30. The trade was a 0.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

• 4 Stocks With Huge Cash Holdings at Silicon Valley Bank

Chan Henry Lee also recently made the following trade(s):

• On Wednesday, March 11th, Chan Henry Lee sold 341 shares of BeOne Medicines stock. The shares were sold at an average price of $300.00, for a total transaction of $102,300.00.
• On Wednesday, February 4th, Chan Henry Lee sold 1,660 shares of BeOne Medicines stock. The shares were sold at an average price of $349.52, for a total transaction of $580,203.20.

BeOne Medicines Price Performance

---

---

Shares of NASDAQ:ONC opened at $309.66 on Friday. The company has a market cap of $33.98 billion, a price-to-earnings ratio of 122.88 and a beta of 0.53. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.41 and a quick ratio of 3.08. The firm has a 50 day simple moving average of $316.84 and a 200 day simple moving average of $324.95. BeOne Medicines Ltd. - Sponsored ADR has a one year low of $218.31 and a one year high of $385.22.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.58 EPS for the quarter, missing the consensus estimate of $1.60 by ($1.02). The company had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.45 billion. BeOne Medicines had a net margin of 5.37% and a return on equity of 10.70%. Research analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BeOne Medicines

Several large investors have recently modified their holdings of the company. Capital International Investors increased its position in shares of BeOne Medicines by 1.3% during the fourth quarter. Capital International Investors now owns 5,113,866 shares of the company's stock worth $1,553,909,000 after buying an additional 67,808 shares during the period. Siren L.L.C. increased its position in shares of BeOne Medicines by 1.4% during the fourth quarter. Siren L.L.C. now owns 500,000 shares of the company's stock worth $151,905,000 after buying an additional 7,010 shares during the period. Morgan Stanley increased its position in shares of BeOne Medicines by 23.9% during the fourth quarter. Morgan Stanley now owns 437,661 shares of the company's stock worth $132,966,000 after buying an additional 84,367 shares during the period. Bank of America Corp DE increased its position in shares of BeOne Medicines by 23.5% during the third quarter. Bank of America Corp DE now owns 345,256 shares of the company's stock worth $117,629,000 after buying an additional 65,763 shares during the period. Finally, Man Group plc increased its position in shares of BeOne Medicines by 18.9% during the fourth quarter. Man Group plc now owns 248,514 shares of the company's stock worth $75,501,000 after buying an additional 39,498 shares during the period. 48.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently commented on ONC. Sanford C. Bernstein raised shares of BeOne Medicines from a "hold" rating to an "outperform" rating and set a $414.00 price objective for the company in a research note on Monday, January 12th. Guggenheim upped their price target on shares of BeOne Medicines from $400.00 to $410.00 and gave the company a "buy" rating in a research report on Friday, February 27th. Wolfe Research began coverage on shares of BeOne Medicines in a research report on Friday, March 27th. They issued an "outperform" rating and a $340.00 price target for the company. Barclays upped their price target on shares of BeOne Medicines from $394.00 to $405.00 and gave the company an "overweight" rating in a research report on Friday, February 27th. Finally, Jefferies Financial Group cut shares of BeOne Medicines from a "buy" rating to a "hold" rating and decreased their price target for the company from $420.00 to $290.00 in a research report on Monday, March 16th. Eleven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, BeOne Medicines has a consensus rating of "Moderate Buy" and a consensus target price of $385.08.

View Our Latest Analysis on ONC

About BeOne Medicines

(Get Free Report)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

See Also

• Five stocks we like better than BeOne Medicines

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].